Healthcare / BiotechnologyNasdaqGS
$3.95
-0.25 (-5.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-59.8M · quality 62.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$148M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-76.7%
↓Gross Margin
N/A
•Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-61.7M · FCF $-52.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $5.0M | $7.0M | $189.6M |
| Net Income | $-61.7M | $-61.7M | $-54.0M | $-62.0M | $117.9M |
| EBITDA | $-59.5M | $-59.5M | $-51.6M | $-59.5M | $120.8M |
| EPS | -1.65 | -1.65 | -1.59 | -1.89 | 3.54 |
| Operating Margin | — | — | -1231.7% | -868.3% | 61.5% |
| Net Margin | — | — | -1087.4% | -880.7% | 62.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.02 | 0.02 | 0.02 |
| Current Ratio | 9.43 | 9.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-52.0M | $-52.0M | $-60.0M | $-59.8M | $117.1M |
| Returns | |||||
| ROE | -76.7% | -76.7% | -38.2% | -35.1% | 50.1% |
| Valuation | |||||
| P/E | — | — | — | — | 1.78 |
| EV/EBITDA | — | — | — | — | 1.05 |
| P/B | 1.83 | 1.83 | 1.17 | 0.79 | 0.89 |
| Growth & Yield | |||||
| Revenue Growth | — | — | -29.4% | -96.3% | — |
| EPS Growth | -3.8% | -3.8% | 15.9% | -153.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.59 → -1.65
Residual
+3.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.